James McCormack BSc

Apr 25, 2024 | onlinelibrary.wiley.com | Blair MacDonald |Ricky Turgeon |James McCormack |James McCormack BSc

NARRATIVE Metformin has historically been the first-line drug option for Type 2 diabetes mellitus, likely based on the UK Prospective Diabetes Study (UKPDS-34 trial), which showed benefits in mortality and myocardial infarction with metformin compared to diet control in overweight patients.1 The finding, however, was muddied by a UKPDS substudy showing metformin increased mortality when added to a sulfonylurea.

Mar 17, 2024 | onlinelibrary.wiley.com | Esteban Dávila |James McCormack |Esteban Davila MD |James McCormack BSc

Corresponding Author Esteban Davila MD Department of Emergency Medicine, New York City Health + Hospitals/Kings County, Brooklyn, New York, USA Correspondence Esteban Davila, Department of Emergency Medicine, New York City Health + Hospitals/Kings County, 451 Clarkson Ave, Brooklyn, NY 11203, USA. Email: [email protected] for more papers by this author